Citadel Advisors LLC Sells 81,045 Shares of Meridian Bioscience Inc. (VIVO)
Citadel Advisors LLC trimmed its position in Meridian Bioscience Inc. (NASDAQ:VIVO) by 48.7% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 85,281 shares of the company’s stock after selling 81,045 shares during the quarter. Citadel Advisors LLC owned about 0.20% of Meridian Bioscience worth $1,343,000 at the end of the most recent quarter.
A number of other institutional investors have also recently added to or reduced their stakes in the stock. Hancock Holding Co. raised its stake in Meridian Bioscience by 18.5% during the 2nd quarter. Hancock Holding Co. now owns 65,254 shares of the company’s stock worth $1,028,000 after acquiring an additional 10,171 shares during the period. Parametric Portfolio Associates LLC lifted its holdings in Meridian Bioscience by 19.2% during the second quarter. Parametric Portfolio Associates LLC now owns 191,114 shares of the company’s stock valued at $3,010,000 after purchasing an additional 30,838 shares in the last quarter. Advisor Group Inc. lifted its holdings in Meridian Bioscience by 24.9% during the second quarter. Advisor Group Inc. now owns 7,720 shares of the company’s stock valued at $122,000 after purchasing an additional 1,537 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Meridian Bioscience by 9.1% during the second quarter. Vanguard Group Inc. now owns 4,018,985 shares of the company’s stock valued at $63,299,000 after purchasing an additional 334,480 shares in the last quarter. Finally, Northern Trust Corp lifted its holdings in Meridian Bioscience by 1.6% during the second quarter. Northern Trust Corp now owns 557,398 shares of the company’s stock valued at $8,780,000 after purchasing an additional 8,886 shares in the last quarter. 87.27% of the stock is owned by institutional investors.
In other news, Chairman John A. Kraeutler acquired 7,000 shares of the firm’s stock in a transaction on Thursday, August 24th. The stock was acquired at an average price of $13.67 per share, for a total transaction of $95,690.00. Following the completion of the transaction, the chairman now owns 345,230 shares in the company, valued at approximately $4,719,294.10. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 2.30% of the company’s stock.
A number of research firms have weighed in on VIVO. Zacks Investment Research lowered shares of Meridian Bioscience from a “buy” rating to a “hold” rating in a research report on Wednesday, June 28th. BidaskClub downgraded shares of Meridian Bioscience from a “buy” rating to a “hold” rating in a research report on Thursday, July 6th. Three investment analysts have rated the stock with a sell rating and four have given a hold rating to the stock. Meridian Bioscience presently has a consensus rating of “Hold” and an average target price of $14.75.
Meridian Bioscience Inc. (VIVO) opened at 14.25 on Wednesday. Meridian Bioscience Inc. has a 1-year low of $10.75 and a 1-year high of $19.75. The company has a market cap of $601.39 million, a price-to-earnings ratio of 28.50 and a beta of 0.84. The stock has a 50 day moving average price of $13.99 and a 200-day moving average price of $14.27.
Meridian Bioscience (NASDAQ:VIVO) last released its quarterly earnings results on Thursday, July 27th. The company reported $0.16 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.16. The company had revenue of $50.14 million for the quarter, compared to analyst estimates of $49.13 million. Meridian Bioscience had a net margin of 10.77% and a return on equity of 16.93%. During the same quarter last year, the business earned $0.21 earnings per share. The firm’s revenue was down 1.0% on a year-over-year basis. On average, equities research analysts forecast that Meridian Bioscience Inc. will post $0.67 EPS for the current year.
ILLEGAL ACTIVITY WARNING: This report was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/10/04/citadel-advisors-llc-sells-81045-shares-of-meridian-bioscience-inc-vivo.html.
Meridian Bioscience Profile
Meridian Bioscience, Inc is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers.
Want to see what other hedge funds are holding VIVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Meridian Bioscience Inc. (NASDAQ:VIVO).
Receive News & Stock Ratings for Meridian Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience Inc. and related stocks with our FREE daily email newsletter.